Comparison Of The Efficacy Of Rescue Therapy For Lamivudine-Resistant Chronic Hepatitis B Between Entecavir Monotherapy And Adefovir ADD-on Lamivudine Combination Therapy:A Meta-Analysis

Objective:To evaluating the efficacy of rescue therapy with ADV plus LAM compared to ETV monotherapy in LAM-resistant CHB patients.Methods:All data of patients with LAM-resistant CHB underwent ETV monotherapy versus adefovir add-on lamivudine combination therapy were collected from literatures by electronic searching and handwork searching. Meta-analysis that recommended by Cochrane Collaboration was done for the data above, 4 researches enrolled in criteria were included in this study using RevMan 5.0 through fixed-effect model and random model.Results:Four eligible trials were included and evaluated for methodologic quality and heterogeneity. Greater virological response was observed in ADV plus LAM compared to ETV monotherapy (P < 0.05). On the contrary, the rate of ALT normalization, HBeAg seroconversion, Virologic breakthough were all similar between ETV plus LAM and ADV (all P > 0.05).Conclusions:The combination of ADV with LAM was superior in inhibiting HBV replication as compared to ETV alone for LAM-resistant CHB patients. So,we can conclude that, in comparison with entecavir monotherapy, adefovir add-on lamivudine combination therapy is more reasonable for the rescue therapy of lamivudine-resistant patients.